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1. Introduction
The first gene therapy that was used on humans was performed for adenosine deaminase
(ADA) deficiency in 1990 [1]. In the early days of gene therapy, it was thought to be a break‐
through in the treatment of a number of human diseases including cancer, cardiovascular
disease, genetic disease, and so on. However, two severe adverse events in gene therapy served
as triggers for the rethinking of the safety of gene therapy. The use of adenoviral gene therapy
in an 18-year-old with an inherited enzyme deficiency at the University of Pennsylvania’s
Institute for Human Gene Therapy resulted in the death of the patient 4 days after the injection
of the vectors into the liver in 1999 [2]. The second accident involved derived carcinogenesis
that was caused by gene therapy that was performed to treat severe combined immunodefi‐
ciency-X1 in 1999 [3]. On the other hand, nonviral vectors (e.g., plasmids, liposomes, polymers,
and so on.) have been developed because of these safety concerns. However, the low effec‐
tiveness of nonviral vectors in gene transduction remains a serious problem.
The key to gene therapy is safety and effectiveness. Sendai virus (SeV) vectors are able to
overcome many of these problems related to gene therapy. The advantages of SeV in terms of
gene therapy are the following: 1) it is nonpathogenic to human, 2) it has a high efficiency of
infection, and 3) it results in high levels of gene expression.
First, we would like to discuss the nonpathogenicity of SeV. The vector that is most used in
gene therapy clinical trials is the Adenovirus, which is followed by the Retrovirus [4]. Ade‐
novirus infections in humans cause pneumonia, bronchitis, croup, and so on. Retrovirus
infections are one of the causes of human carcinogenesis or immunodeficiency. These vectors
are pathogenic to human beings. Moreover, the infection of these vectors to human cells is
associated with the risk of viral gene integration into the human genome, which contributes
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to gene mutations or structural changes to chromosomes. On the other hand, SeV was
originally discovered as the cause of pneumonia in rodents. Because the SeV gene exists as
RNA in the cell cytoplasm throughout the life cycle of the virus from infection of the target
cells to viral budding, no genetic toxicities have been confirmed (Figure 1). For these reasons,
the risk of pathogenicity to humans is surprisingly low, and its safety has already been assured
when it is used as a gene therapy drug.
Second, we would like to discuss the features of SeV with respect to its high efficiency of
infection. Hemagglutinin-neuraminidase (HN) proteins recognize sialic acid, which is
expressed as a glycoprotein or glycolipid on the cell surface. Sialic acid is widely expressed in
the cells of mammals or other species, and its expression enables a large variety of SeV
infections, such as those in the airway epithelium [5], saphenous vein [6], or in a variety of
tumors [7,8]. In contrast, adenoviruses require the coxsackievirus–adenovirus receptor (CAR)
to attach to cells, and the CAR is selectively expressed among cells, which limits its infection.
In addition, adenovirus-mediated gene transfer requires a relatively long exposure time to
reach maximum gene transfer efficiency, and this is a common characteristic of other currently
available vectors. In contrast, SeV can infect cells in a minute or less [6]. Moreover, SeV can
infect dividing cells or nondividing cells.
The third feature of SeV is its high level of gene expression. SeV has a dramatically high gene
transfer efficiency compared with adenovirus vectors [6,9]. Namely, SeV can efficiently load
a therapeutic gene, and gene therapy using SeV is able to decrease the amount of administra‐
tion vectors in the clinical setting, resulting in a lower risk of gene therapy.
We examined whether we can apply these outstanding characteristics of SeV to the gene therapy
of cancer. In this chapter, we describe the history of the investigations of oncolytic gene therapy
using SeV, the present developmental status of this therapy, and the future of this therapy.
Figure 1. Redrawn with permission from Kinoh H et al., Front Biosci. 2008 Jan 1;13:2327-34. The life cycle of the Sen‐
dai Virus (SeV) and other vectors. SeV, Measles, and the Newcastle Disease Virus (NDV) do not result in chromosomal
integration, whereas other existing vectors do. AAV, adeno-associated virus.
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2. Structure of SeV
SeV is a negative-sense, single-stranded RNA virus of the Paramyxoviridae family. SeV
genome consists of 15,384 base pairs and encodes the following 6 genes: nucleocapsid protein
(N), which binds to RNA; phosphoprotein (P), which forms a small subunit of RNA polymer‐
ase; matrix protein (M), which lines the inside of viral particles; fusion protein (F), which is
important for host cell penetration; HN, which is involved in the attachment to the host cells;
and large protein (L), which forms a big subunit of RNA polymerase. The HN protein serves
in the attachment to target cells by recognizing sialic acid on the cell surface. The F protein is
cleaved through conformational change into F1 and F2, and this is triggered by local enzymatic
activity, particularly that of trypsin. The cleaved F protein penetrates into the cellular mem‐
brane, which induces the membrane and the viral envelope to merge [10].
Figure 2. Schematic model and electron microscope photograph of SeV.
3. Fusogenic activity of SeV
Yoshio Okada discovered the phenomenon that SeV causes the fusion of Ehrlich’s tumor cells
[11]. Paramixoviridae family members including SeV have the property of cell-to-cell fusion.
The fusion process, which occurs between the viral envelope and cells, may also occur between
adjacent viral-infected cells when the Fusion protein is expressed on the cell surface, thus
causing extensive membrane fusion and the formation of a syncytium. Cell-to-cell fusion
induces apoptotic signals, resulting in cell death [12,13].
3.1. Oncolytic virotherapy with SeV
We have applied these fusogenic activity characteristics of SeV to cancer therapy. It is impor‐
tant in gene therapy for the treatment of cancer that 1) tumor-specific infections are enhanced
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and 2) secondary infection is prevented. In order to obtain these properties, we modified the
SeV gene by altering the F gene and deleting the M gene.
First, we would like to describe the background of the tumor-specificity abilities of BioknifeTM.
We focused our attention on the urokinase-type plasminogen activator (uPA). uPA is a trypsin-
like serine protease that is synthesized and secreted as pro-uPA, which has little or no
proteolytic activity [14]. The urokinase-type plasminogen activator receptor (uPAR) is a 55–
60-kD glycoprotein that is anchored on the cell surface by a glycosyl-phosphatidylinositol
linkage [15,16]. uPA binds to uPAR with high affinity. uPAR anchors uPA to the cell membrane
and converts pro-uPA to active uPA, thereby localizing the proteolytic activity around the cell
surface [17]. Activated uPA plays an important role in extracellular matrix degradation and
results in tumor invasion and metastasis [18]. A wide variety of cancers overexpress uPAR
and are associated with poor prognosis [19-23]. However, uPAR is expressed less in normal
tissue except for in unusual circumstances such as inflammation [21,22,24].
Figure 3. Schematic model of the urokinase activation system.
Bound and inactive pro-urokinase-type plasminogen activator (uPA) is converted to active
uPA, inducing extracellular matrix (ECM) degradation. As a result, tumor invasion and
metastasis are promoted.
Given that uPA activity is high around tumor cells and low around nontumor cells, we
converted the F gene, which is specific to Trypsin in the wild type SeV, to a uPA-specific
sequence (Figure 4). As a result, we succeeded in fusing infected cells to tumor cells only.
Moreover, to optimize the fusion ability, the F gene was given an additional change, which
truncated the cytoplasmic domain of the F protein (Figure 4). This genetic modification
resulted in more efficient fusogenic abilities [8].
Second, we would like to describe the background of the deleting of the M gene (Figure 5).
Deletion of the M gene resulted in avoidance of the budding of secondary viral particles
because the M protein is indispensable for the budding of SeV. Consequently, the F proteins
and HN proteins, which are expected to be the second particles in the viral spike, accumulate
on the infected cell surface. If uPA is activated around the cell surface, the recombinant F
Novel Gene Therapy Approaches186
protein is cleaved, and the contiguous cells go into chain fusion reaction. These completely
inhibited secondary viral particles served not only to promote fusion efficiency, but also to
improve gene therapy safety.
I would like to emphasize that the oncolysis that is mediated by BioKnifeTM is entirely different
from conventional oncolysis. Oncolytic viruses, which is a term used to describe most viruses
such as adenovirus or herpes simplex viruses, provoke the disruption of infected cells with a
large number of secondary viral particles. However, the production of secondary viruses by
these oncolytic viruses may limit gene therapy with respect to safety. Thus, a large number of
viruses may evoke viremia and induce uncontrollable inflammatory reactions. In contrast, the
oncolysis that is caused by BioKnifeTM is cell death that is mediated by caspase-dependent
apoptosis [13,25]. There is no need to worry about viremia, even if an explosive spread of
infection is observed.
Figure 5. Gene structure of recombinant SeV. Wild type SeV is pictured at the top of the figure, which is followed by the M-
gene deleted SeV with a substitutive load of the Green fluorescent protein (GFP) gene (rSeV/dM-GFP) in the middle. Final‐
ly, at the bottom, the F gene of rSeV/dM-GFP is transformed to a uPA-sensitive sequence (BioKnifeTM-GFP).
4. The potential of BioKnifeTM
To test the cytotoxicity of BioknifeTM against tumor cells, we conducted an in vitro infection
experiment in many types of tumor cells. Cell fusion and cell death were observed in many
tumor types, and this was dependent on the uPA activity of the tumor cells. As expected,
Figure 4. Modification of the cleavage site of the SeV-F protein, which is sensitive to the urokinase-type plasminogen
activator, and truncation of the cytoplasmic tail resulted in optimization of the cell-fusion activity.
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nontumor cells were not injured [8]. Next, we tested the antitumor efficacy of BioKnifeTM in
vivo. Cells of the human prostate tumor cell line, PC3, were implanted into a nude mouse, and
then BioKnifeTM was injected into the tumor. BioKnifeTM-infected tumor presented GFP
fluorescence from day 1 with the maximum GFP intensity on day 7. A microscopic examination
of the subcutaneous tumor on day 16 showed that the tumor cells had been eradicated.
Figure 6. A time-course analysis of BioKnifeTM infection of subcutaneously inoculated PC3 tumor cells in a nude
mouse. Photomicrographs of tissue specimens on day 16 are presented in the bottom two panels.
5. BioKnifeTM infections create a positive feedback loop of cell-to-cell
fusion
The cell-to-cell fusion that is mediated by BioknifeTM provided another effect. We demonstrat‐
ed that BioknifeTM infections induce simultaneous activation of the uPA expression. In
addition, we found that the induction of uPA is mediated by the retinoic acid-inducible gene-1
(RIG-I), which is a viral RNA sensor that is activated by BioknifeTM infection and which
activates the nuclear factor-kappa B (NF-κB) signaling pathway [25]. Activated RIG-I upre‐
gulates levels of uPA expression through the downstream protein, NFκB. Extracellularly
secreted uPA binds uPAR on the tumor surface, which increases the activity of uPA. As a result,
the F protein on BioKnifeTM-infected cells is activated and cleaved, resulting in cell fusion. It
is possible that BioKnifeTM results in self-induced fusion (Figure 7). This phenomenon suggests
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that uPAR is necessary for the cell fusion that is mediated by BioKnifeTM, even if uPA is not
expressed in tumor cells, and BioKnifeTM infection itself facilitates the fusion activity.
Figure 7. A schematic model of the induction of uPA expression through BioknifeTM infection. Retinoic acid-inducible
gene-1 (RIG-I) activation promotes the fusion cascade.
In summary, we have demonstrated the potential and the mechanisms of BioknifeTM with
numerous fundamental experiments. Admittedly, BioKnifeTM has no ability to infect distant
tumor lesions or metastatic lesions through intravascular routes because of its instability in
the blood. However, the ability of local infections of the tumor cells and the killing power are
outstanding. Next, we explored diseases in which gene therapy using BioKnifeTM can be
applied. We examined malignant mesothelioma (MPM) in particular.
MPM is a malignancy that arises from the pleural cavity. Because MPM has a long latency
period after the inhalation of asbestos [26], the number of deaths by MPM is expected to
increase in the next several decades, reflecting the past usage of asbestos [27]. MPM is highly
malignant due to its intractableness to treatment. Although a large number of studies have
examined approaches to MPM therapy, no marked progress has appeared to overcome this
disease. The median overall survival rate is less than 30 months, even if it is treated with
multimodality therapy [28,29]. Thus, novel therapeutics are highly desired. MPM spreads
widely throughout the pleural cavity and rarely metastasizes to distant sites in the earlier stage.
In addition, MPM expresses high levels of uPAR. These characteristics suggest favorable
conditions for gene therapy with BioknifeTM. Thus, we explored the possibility of treatment
with BioknifeTM in this disease.
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6. Antitumor effects of BioknifeTM in a MPM orthotopic murine model
To confirm the antitumor effects in MPM, we first established two independent human
orthotopic murine models. The human MPM cell lines, MSTO-211H (biphasic subtype) and
H226 (epithelioid subtype), were injected into the thoracic cavity of Balb/c nu/nu mice. The
tumor cells spread and formed multiple nodules in the thoracic cavity, which is similar to the
pathology observed during the clinical course of human MPM. Untreated mice eventually died
due to MPM progression. We assessed the performance of BioknifeTM in these MPM murine
models. MPM-bearing mice were treated with BioKnifeTM at the following frequencies: once,
three times, or six times. The result was that, in both murine models, BioKnifeTM-treated cohort
exhibited a significantly prolonged survival compared with the control group. The greater the
number of BioKnifeTM injection times, the higher the survival rate. In the group receiving 6
injections of BioKnifeTM, long-term survivors were observed.
Figure 8. Kaplan–Meier survival plot of BALB/c nude mice bearing H226 or MSTO-211H tumors that were left untreat‐
ed or treated with phosphate-buffered saline or BioKnifeTM in multicycle treatments. No treat indicates no treatment,
PBS indicates phosphate- buffered saline treatment, and BK indicates BioKnifeTM treatment.
Considering these findings, MPM is a good target for BioKnifeTM treatment because the
biological characteristics of MPM match the characteristics of BioKnifeTM. MPM spreads in the
thoracic cavity and rarely develops distant metastasis. BioKnifeTM can spread to adjacent tumor
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cells, and local control is its primary advantage. Moreover, we would like to emphasize the
accessibility of BioKnifeTM in treatments of MPM. We suggest that video-assisted thoracoscopic
surgery (VATS) and chest tubes are the best way to administer BioKnifeTM. MPM often forms
nodular lesions on the pleural surface. For these targets, it is best to inject BioKnifeTM intratu‐
morally with VATS. In addition, because MPM frequently produces malignant pleural effusion
[30], most cases need chest tubes. In these cases, it is convenient to administer BioKnifeTM
intrapleurally through the chest tube. This access route enables us to administer BioKnifeTM
repeatedly and safely because multiple cycles of the administration of BioKnifeTM are more
effective (Figure 8). Based on these results, we are planning a clinical trial using BioKnifeTM to
treat MPM.
7. BioKnifeTM in the future
We described above the developmental history and the usefulness of BioKnifeTM. It should be
noted that BioKnifeTM has the ability to load other treatment genes, cytokines, tumor sup‐
pressing genes, or cancer antigens. Amazingly, the cytotoxicity of BioKnifeTM depends solely
on its fusion ability. In other words, there is still considerable room for improvements of this
treatment modality. Moreover, there is room for further examination of the relationship
between BioKnifeTM and cancer immunity. Viral oncolysate is applied as a cancer vaccine in
cancer immunotherapy. BioKnifeTM-lysed tumor cells make an extract of tumor cells. The
extract contains both cancer cell proteins and virus proteins. This extract may facilitate the
antigen presentation activity to dendritic cells or activate natural killer cells. Further studies
are necessary to confirm this fact.
8. Conclusion
We developed BioKnifeTM, which is a uPA activity-dependent oncolytic SeV vector. This
promising oncolytic vector, BioKnifeTM, may overcome the limitations of current gene therapy
vectors. Further studies are needed to examine whether this new modality is effective in the
clinical setting as a therapeutic alternative for this intractable disease.
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